Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials
Crossref DOI link: https://doi.org/10.1007/s40262-017-0580-y
Published Online: 2017-07-25
Published Print: 2018-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Khatri, Amit
Goss, Sandra
Jiang, Ping
Mansikka, Heikki
Othman, Ahmed A.
Funding for this research was provided by:
AbbVie
License valid from 2017-07-25